论文部分内容阅读
目的通过动物实验探讨恶性肿瘤体内化疗的疗效与肿瘤细胞体外药物敏感性预测的关系。方法采用浓度梯度递增法制备小鼠淋巴瘤 EL4耐药细胞系 EI4/美法仑,四甲基偶氮唑蓝(MTY)比色法检测其在体外对美法仑的耐药指数。利用单一剂量化疗药物治愈荷瘤小鼠的动物模型,将等量 EL4/美法仑和 EL4细胞分别接种在野生型 C57BL6小鼠皮下,接种后12 d,荷 EL4/美法仑肿瘤小鼠和荷 EL4肿瘤小鼠分别再随机分为美法仑治疗组和对照组,每组各5只。美法仑治疗组荷瘤小鼠腹腔内单次注射7.5 m/kg 的美法仑,对照组荷瘤小鼠腹腔内注射等量生理盐水。随后观察各组荷瘤小鼠肿瘤结节直径的变化。结果 EL4/美法仑耐药细胞和 EL41细胞形态上肉眼无明显区别,EL4/美法仑细胞可在含5μg/ml 美法仑的培养基中长期存活,其对美法仑的耐药指数为2.87。动物体内实验发现7.5 mg/kg 美法仑不仅能使荷 EL4肿瘤小鼠的肿瘤结节消退,而且也能使荷 EL4/美法仑肿瘤小鼠的肿瘤治愈。结论恶性肿瘤体内化疗的疗效与肿瘤细胞在体外是否对该化疗药物耐药无关,在体外对美法仑耐药的肿瘤细胞对美法仑的体内治疗仍敏感。
Objective To investigate the relationship between the curative effect of chemotherapy in malignant tumor in vivo and the prediction of drug sensitivity of tumor cells in vitro through animal experiments. Methods EL4 drug-resistant cell line EI4 / melphalan and MTY assay were used to detect the resistance index of melphalan to melphalan in vitro. An animal model of tumor-bearing mice was treated with a single dose of chemotherapeutic drug. Equivalent amounts of EL4 / melphalan and EL4 cells were inoculated subcutaneously in wild-type C57BL6 mice, respectively. At 12 days after inoculation, mice bearing EL4 / melphalan and EL4 tumor-bearing mice were randomly divided into melphalan treatment group and control group, 5 in each group. The melphalan-treated mice were injected intraperitoneally with a single injection of melphalan at a dose of 7.5 m / kg. The control mice were intraperitoneally injected with the same amount of saline. Then observed the tumor-bearing mice in each group changes in the diameter of the tumor. Results EL4 / melphalan drug-resistant cells and EL41 cells morphologically no significant difference between the naked eye, EL4 / melphalan cells in 5μg / ml melphalan medium long-term survival of its melphalan resistance index Is 2.87. In vivo experiments in animals found that 7.5 mg / kg of melphalan not only regressed tumor nodules in EL4 tumor-bearing mice but also tumors in EL4 / melphalan-bearing tumor-bearing mice. Conclusion The efficacy of chemotherapy in malignant tumors in vivo is independent of whether the tumor cells are resistant to the chemotherapeutic drugs in vitro. In vitro treatment of melphalan-resistant tumor cells is still sensitive to melphalan in vivo.